Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Disrupting Myelin-Specific Th17 Cell Gut Homing Confers Protection in an Adoptive Transfer Experimental Autoimmune Encephalomyelitis.

Duc D, Vigne S, Bernier-Latmani J, Yersin Y, Ruiz F, Gaïa N, Leo S, Lazarevic V, Schrenzel J, Petrova TV, Pot C.

Cell Rep. 2019 Oct 8;29(2):378-390.e4. doi: 10.1016/j.celrep.2019.09.002.

2.

Factors influencing patient satisfaction with the first diagnostic consultation in multiple sclerosis: a Swiss Multiple Sclerosis Registry (SMSR) study.

Kamm CP, Barin L, Gobbi C, Pot C, Calabrese P, Salmen A, Achtnichts L, Kesselring J, Puhan MA, von Wyl V; Swiss Multiple Sclerosis Registry (SMSR).

J Neurol. 2019 Oct 8. doi: 10.1007/s00415-019-09563-y. [Epub ahead of print]

PMID:
31595377
3.

Oxysterols in Autoimmunity.

Duc D, Vigne S, Pot C.

Int J Mol Sci. 2019 Sep 12;20(18). pii: E4522. doi: 10.3390/ijms20184522. Review.

4.

The "central vein sign" in patients with diagnostic "red flags" for multiple sclerosis: A prospective multicenter 3T study.

Maggi P, Absinta M, Sati P, Perrotta G, Massacesi L, Dachy B, Pot C, Meuli R, Reich DS, Filippi M, Pasquier RD, Théaudin M.

Mult Scler. 2019 Sep 19:1352458519876031. doi: 10.1177/1352458519876031. [Epub ahead of print]

PMID:
31536435
5.

How do patients enter the healthcare system after the first onset of multiple sclerosis symptoms? The influence of setting and physician specialty on speed of diagnosis.

Barin L, Kamm CP, Salmen A, Dressel H, Calabrese P, Pot C, Schippling S, Gobbi C, Müller S, Chan A, Rodgers S, Kaufmann M, Ajdacic-Gross V, Steinemann N, Kesselring J, Puhan MA, von Wyl V; Swiss Multiple Sclerosis Registry.

Mult Scler. 2019 Jan 18:1352458518823955. doi: 10.1177/1352458518823955. [Epub ahead of print]

PMID:
31456464
6.

The EBI2-oxysterol axis promotes the development of intestinal lymphoid structures and colitis.

Wyss A, Raselli T, Perkins N, Ruiz F, Schmelczer G, Klinke G, Moncsek A, Roth R, Spalinger MR, Hering L, Atrott K, Lang S, Frey-Wagner I, Mertens JC, Scharl M, Sailer AW, Pabst O, Hersberger M, Pot C, Rogler G, Misselwitz B.

Mucosal Immunol. 2019 May;12(3):733-745. doi: 10.1038/s41385-019-0140-x. Epub 2019 Feb 11.

7.

Factors associated with time from first-symptoms to diagnosis and treatment initiation of Multiple Sclerosis in Switzerland.

Kaufmann M, Kuhle J, Puhan MA, Kamm CP, Chan A, Salmen A, Kesselring J, Calabrese P, Gobbi C, Pot C, Steinemann N, Rodgers S, von Wyl V; Swiss Multiple Sclerosis Registry (SMSR).

Mult Scler J Exp Transl Clin. 2018 Dec 6;4(4):2055217318814562. doi: 10.1177/2055217318814562. eCollection 2018 Oct-Dec.

8.

Patterns of care for Multiple Sclerosis in a setting of universal care access: A cross-sectional study.

Barin L, Kaufmann M, Salmen A, Kamm CP, Gobbi C, Kuhle J, Pot C, Chan A, Czaplinski A, Ajdacic-Gross V, Rodgers S, Kesselring J, Puhan MA, von Wyl V; Swiss Multiple Sclerosis Registry.

Mult Scler Relat Disord. 2019 Feb;28:17-25. doi: 10.1016/j.msard.2018.11.033. Epub 2018 Dec 2.

PMID:
30530118
9.

The Swiss Multiple Sclerosis Registry (SMSR): study protocol of a participatory, nationwide registry to promote epidemiological and patient-centered MS research.

Steinemann N, Kuhle J, Calabrese P, Kesselring J, Disanto G, Merkler D, Pot C, Ajdacic-Gross V, Rodgers S, Puhan MA, von Wyl V; Swiss Multiple Sclerosis Registry.

BMC Neurol. 2018 Aug 13;18(1):111. doi: 10.1186/s12883-018-1118-0.

10.

The disease burden of Multiple Sclerosis from the individual and population perspective: Which symptoms matter most?

Barin L, Salmen A, Disanto G, Babačić H, Calabrese P, Chan A, Kamm CP, Kesselring J, Kuhle J, Gobbi C, Pot C, Puhan MA, von Wyl V; Swiss Multiple Sclerosis Registry (SMSR).

Mult Scler Relat Disord. 2018 Oct;25:112-121. doi: 10.1016/j.msard.2018.07.013. Epub 2018 Jul 21.

PMID:
30059895
11.

IL-27-Induced Type 1 Regulatory T-Cells Produce Oxysterols that Constrain IL-10 Production.

Vigne S, Chalmin F, Duc D, Clottu AS, Apetoh L, Lobaccaro JA, Christen I, Zhang J, Pot C.

Front Immunol. 2017 Sep 25;8:1184. doi: 10.3389/fimmu.2017.01184. eCollection 2017.

12.

Increased interleukin-27 cytokine expression in the central nervous system of multiple sclerosis patients.

Lalive PH, Kreutzfeldt M, Devergne O, Metz I, Bruck W, Merkler D, Pot C.

J Neuroinflammation. 2017 Jul 24;14(1):144. doi: 10.1186/s12974-017-0919-1.

13.

EBI2 Expression and Function: Robust in Memory Lymphocytes and Increased by Natalizumab in Multiple Sclerosis.

Clottu AS, Mathias A, Sailer AW, Schluep M, Seebach JD, Du Pasquier R, Pot C.

Cell Rep. 2017 Jan 3;18(1):213-224. doi: 10.1016/j.celrep.2016.12.006.

14.

The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options.

Disanto G, Benkert P, Lorscheider J, Mueller S, Vehoff J, Zecca C, Ramseier S, Achtnichts L, Findling O, Nedeltchev K, Radue EW, Sprenger T, Stippich C, Derfuss T, Louvion JF, Kamm CP, Mattle HP, Lotter C, Du Pasquier R, Schluep M, Pot C, Lalive PH, Yaldizli Ö, Gobbi C, Kappos L, Kuhle J; SMSC Scientific Board.

PLoS One. 2016 Mar 31;11(3):e0152347. doi: 10.1371/journal.pone.0152347. eCollection 2016.

15.

IL-27 Induces Th17 Differentiation in the Absence of STAT1 Signaling.

Peters A, Fowler KD, Chalmin F, Merkler D, Kuchroo VK, Pot C.

J Immunol. 2015 Nov 1;195(9):4144-53. doi: 10.4049/jimmunol.1302246. Epub 2015 Sep 25.

16.

Oxysterols regulate encephalitogenic CD4(+) T cell trafficking during central nervous system autoimmunity.

Chalmin F, Rochemont V, Lippens C, Clottu A, Sailer AW, Merkler D, Hugues S, Pot C.

J Autoimmun. 2015 Jan;56:45-55. doi: 10.1016/j.jaut.2014.10.001. Epub 2014 Nov 10.

PMID:
25456971
17.

Ag-presenting CpG-activated pDCs prime Th17 cells that induce tumor regression.

Guéry L, Dubrot J, Lippens C, Brighouse D, Malinge P, Irla M, Pot C, Reith W, Waldburger JM, Hugues S.

Cancer Res. 2014 Nov 15;74(22):6430-40. doi: 10.1158/0008-5472.CAN-14-1149. Epub 2014 Sep 24.

18.

Metallothioneins negatively regulate IL-27-induced type 1 regulatory T-cell differentiation.

Wu C, Pot C, Apetoh L, Thalhamer T, Zhu B, Murugaiyan G, Xiao S, Lee Y, Rangachari M, Yosef N, Kuchroo VK.

Proc Natl Acad Sci U S A. 2013 May 7;110(19):7802-7. doi: 10.1073/pnas.1211776110. Epub 2013 Apr 29.

19.

SOCS3 transactivation by PPARγ prevents IL-17-driven cancer growth.

Berger H, Végran F, Chikh M, Gilardi F, Ladoire S, Bugaut H, Mignot G, Chalmin F, Bruchard M, Derangère V, Chevriaux A, Rébé C, Ryffel B, Pot C, Hichami A, Desvergne B, Ghiringhelli F, Apetoh L.

Cancer Res. 2013 Jun 15;73(12):3578-90. doi: 10.1158/0008-5472.CAN-12-4018. Epub 2013 Apr 25.

20.

Nogo-A downregulation improves insulin secretion in mice.

Bonal CB, Baronnier DE, Pot C, Benkhoucha M, Schwab ME, Lalive PH, Herrera PL.

Diabetes. 2013 May;62(5):1443-52. doi: 10.2337/db12-0949. Epub 2012 Dec 28.

21.

Evaluating manual inflations and breathing during mask ventilation in preterm infants at birth.

Schilleman K, van der Pot CJ, Hooper SB, Lopriore E, Walther FJ, te Pas AB.

J Pediatr. 2013 Mar;162(3):457-63. doi: 10.1016/j.jpeds.2012.09.036. Epub 2012 Oct 25.

PMID:
23102793
22.

Aryl hydrocarbon receptor controls regulatory CD4+ T cell function.

Pot C.

Swiss Med Wkly. 2012 May 31;142:w13592. doi: 10.4414/smw.2012.13592. eCollection 2012. Review.

23.

Proteolytic Cleavage of the Red Blood Cell Glycocalyx in a Genetic Form of Hypertension.

Pot C, Chen AY, Ha JN, Schmid-Schönbein GW.

Cell Mol Bioeng. 2011 Dec 1;4(4):678-692.

24.

Induction of regulatory Tr1 cells and inhibition of T(H)17 cells by IL-27.

Pot C, Apetoh L, Awasthi A, Kuchroo VK.

Semin Immunol. 2011 Dec;23(6):438-45. doi: 10.1016/j.smim.2011.08.003. Epub 2011 Sep 3. Review.

25.

Type 1 regulatory T cells (Tr1) in autoimmunity.

Pot C, Apetoh L, Kuchroo VK.

Semin Immunol. 2011 Jun;23(3):202-8. doi: 10.1016/j.smim.2011.07.005. Epub 2011 Aug 12. Review.

26.

The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27.

Apetoh L, Quintana FJ, Pot C, Joller N, Xiao S, Kumar D, Burns EJ, Sherr DH, Weiner HL, Kuchroo VK.

Nat Immunol. 2010 Sep;11(9):854-61. doi: 10.1038/ni.1912. Epub 2010 Aug 1.

27.

Molecular pathways in the induction of interleukin-27-driven regulatory type 1 cells.

Pot C, Apetoh L, Awasthi A, Kuchroo VK.

J Interferon Cytokine Res. 2010 Jun;30(6):381-8. doi: 10.1089/jir.2010.0047. Review.

28.

Cutting edge: IL-27 induces the transcription factor c-Maf, cytokine IL-21, and the costimulatory receptor ICOS that coordinately act together to promote differentiation of IL-10-producing Tr1 cells.

Pot C, Jin H, Awasthi A, Liu SM, Lai CY, Madan R, Sharpe AH, Karp CL, Miaw SC, Ho IC, Kuchroo VK.

J Immunol. 2009 Jul 15;183(2):797-801. doi: 10.4049/jimmunol.0901233. Epub 2009 Jul 1.

29.

Cutting edge: IL-23 receptor gfp reporter mice reveal distinct populations of IL-17-producing cells.

Awasthi A, Riol-Blanco L, Jäger A, Korn T, Pot C, Galileos G, Bettelli E, Kuchroo VK, Oukka M.

J Immunol. 2009 May 15;182(10):5904-8. doi: 10.4049/jimmunol.0900732.

30.

Human herpesvirus-6 variant A encephalomyelitis.

Pot C, Burkhard PR, Villard J, Perrin L, Kaiser L, Landis T, Lalive PH.

Neurology. 2008 Mar 18;70(12):974-6. doi: 10.1212/01.wnl.0000297197.79009.31. No abstract available.

PMID:
18347321
31.

Synaptic destabilization by neuronal Nogo-A.

Aloy EM, Weinmann O, Pot C, Kasper H, Dodd DA, Rülicke T, Rossi F, Schwab ME.

Brain Cell Biol. 2006 Jun;35(2-3):137-56. Epub 2007 Oct 4.

PMID:
17957480
32.

Combined antiviral-immunosuppressive treatment in human T-lymphotrophic virus 1-Sjögren-associated myelopathy.

Pot C, Chizzolini C, Vokatch N, Tiercy JM, Ribi C, Landis T, Perren F.

Arch Neurol. 2006 Sep;63(9):1318-20.

PMID:
16966512
33.

Apomorphine-induced eosinophilic panniculitis and hypereosinophilia in Parkinson disease.

Pot C, Oppliger R, Castillo V, Coeytaux A, Hauser C, Burkhard PR.

Neurology. 2005 Jan 25;64(2):392-3. No abstract available.

PMID:
15668455
34.

Nogo-A expressed in Schwann cells impairs axonal regeneration after peripheral nerve injury.

Pot C, Simonen M, Weinmann O, Schnell L, Christ F, Stoeckle S, Berger P, Rülicke T, Suter U, Schwab ME.

J Cell Biol. 2002 Oct 14;159(1):29-35. Epub 2002 Oct 14.

35.

Prolonged arthritis, viraemia, hypogammaglobulinaemia, and failed seroconversion following rubella immunisation.

Tingle AJ, Pot CH, Chantler JK.

Lancet. 1984 Jun 30;1(8392):1475-6. No abstract available.

PMID:
6145919
36.

In-vitro activity of cefoperazone and penicillins alone and in combination with aminoglycosides against Pseudomonas aeruginosa.

Hoogkamp-Korstanje JA, Pot CM, Westerdaal NA.

J Antimicrob Chemother. 1981 Aug;8(2):101-6. No abstract available.

PMID:
6456254
37.

[Psychiatry and physiotherapy; from team work to joint treatment].

Pot CE, van Luin JF.

Ned Tijdschr Geneeskd. 1981 May 9;125(19):749-52. Dutch. No abstract available.

PMID:
7242722
38.

Feedback inhibition by human primed T-helper cells.

Heijnen CJ, Uytdehaag F, Pot CH, Ballieux RE.

Nature. 1979 Aug 16;280(5723):589-91. No abstract available.

PMID:
313527
39.

[A controlled oxygenation tank for the lasting survival of non-perfused myocardial tissue of adult mammals].

Coraboeuf E, Denoit F, Vassort G, Pot C.

J Physiol (Paris). 1969 Sep-Oct;61(5):443-6. French. No abstract available.

PMID:
5376823
40.

[Infections transmitted from animal to man; hepatonephritis having as etiologic agent an element beside the psittacosis group, at the lower limits of the rickettsiae].

GIROUD P, JADIN J, ROGER F, DUMAS N, POT C, PITALLIER M.

Bull Mem Soc Med Hop Paris. 1955 May 13-20;71(15-16):548-50. French. No abstract available.

PMID:
13240456
41.

[Lobstein disease; genealogical study].

MARQUEZY RA, BACH C, TROISIER MF, POT C.

Bull Mem Soc Med Hop Paris. 1951 Mar 9-16;67(9-10):305-9. Undetermined Language. No abstract available.

PMID:
14839502

Supplemental Content

Support Center